MedPath

深圳立健药业有限公司

Ownership
-
Established
2001-04-28
Employees
-
Market Cap
-
Website
http://www.lijian-pharm.com

Clinical Trials

0

Active:0
Completed:0

Trial Phases

0 Phases

Drug Approvals

53

NMPA:53

Drug Approvals

Daptomycin for Injection

Product Name
注射用达托霉素
Approval Number
国药准字H20243324
Approval Date
Mar 12, 2024
NMPA

Cefazolin Sodium for Injection

Product Name
注射用头孢唑林钠
Approval Number
国药准字H20143066
Approval Date
Nov 27, 2023
NMPA

Cefazolin Sodium for Injection

Product Name
注射用头孢唑林钠
Approval Number
国药准字H20143067
Approval Date
Nov 27, 2023
NMPA

Cefprozil for Suspension

Product Name
头孢丙烯干混悬剂
Approval Number
国药准字H20234253
Approval Date
Sep 28, 2023
NMPA

Cefdinir Capsules

Product Name
头孢地尼胶囊
Approval Number
国药准字H20233924
Approval Date
Jul 11, 2023
NMPA

Ceftezole Sodium for Injection

Product Name
注射用头孢替唑钠
Approval Number
国药准字H20084563
Approval Date
Jul 7, 2023
NMPA

Ceftezole Sodium for Injection

Product Name
注射用头孢替唑钠
Approval Number
国药准字H20084159
Approval Date
Jun 14, 2023
NMPA

Ceftezole Sodium for Injection

Product Name
注射用头孢替唑钠
Approval Number
国药准字H20084158
Approval Date
Jun 14, 2023
NMPA

Cefaclor Granules

Product Name
头孢克洛颗粒
Approval Number
国药准字H20083647
Approval Date
Dec 5, 2022
NMPA

Cefaclor Capsules

Product Name
头孢克洛胶囊
Approval Number
国药准字H20083645
Approval Date
Nov 15, 2022
NMPA
  • Prev
  • 1
  • 2
  • 3
  • 4
  • 5
  • 6
  • Next

Clinical Trials

No trials found

News

No news found

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.